Leading U.S. proxy advisory firm supports Teva nominees and other shareholders’ meeting proposals
Posted: 17 July 2014 | | No comments yet
Teva Pharmaceutical Industries Ltd. reported that ISS Proxy Advisory Services, the leading U.S. independent proxy advisory firm, recommended that shareholders vote in favor of all Teva nominees for director…
![TEVA LOGO](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/TEVA_LOGO.gif)
![TEVA LOGO](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/TEVA_LOGO.gif)
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) reported today that ISS Proxy Advisory Services, the leading U.S. independent proxy advisory firm, recommended that shareholders vote in favor of all Teva nominees for director (Messrs. Jean-Michel Halfon, Joseph (Yossi) Nitzani, Dan Propper and Ory Slonim) and for each of the other proposals on the agenda for consideration at the Company’s upcoming annual general meeting of shareholders.
ISS provides voting analysis on more than 20,000 shareholder meetings per year to mutual funds, financial institutions and hedge funds.